Physician profile
Richard A Hellander
NPI 1003846932
$2,993.56
in general payments reported to CMS, 2019-2025
25 companies · $521 in 2025
The $521 reported for 2025 was more than what 78% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $112 · 2021: $309 · 2022: $351 · 2023: $776 · 2024: $788 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $732.83 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Braeburn INC. | $476.92 | 2023-2025 | Brixadi |
| Alkermes, INC. | $375.84 | 2021-2025 | Vivitrol, Vivitrol |
| Lilly USA, LLC | $292.31 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $259.69 | 2023-2025 | Shingrix, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.35 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $94.95 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astrazeneca Pharmaceuticals Lp | $78.61 | 2021-2024 | Farxiga |
| Dexcom, INC. | $78.37 | 2022-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $77.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.10 | 2021-2022 | |
| Pfizer INC. | $49.99 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.19 | 2020-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $30.15 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $28.13 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $27.67 | 2024 | Nuzyra |
| Gilead Sciences, INC. | $17.67 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.19 | 2024 | Xifaxan |
| Medtronic, INC. | $15.08 | 2025 | Minimed 780g |
| Qiagen, LLC | $14.17 | 2021 | |
| Amarin Pharma, INC. | $13.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.95 | 2020 | |
| Nabriva Therapeutics, Plc | $11.87 | 2020 | |
| Amgen INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hellander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.